Dr Jordi Monés explains the huge impact of atrophic AMD at the Iveric Bio Zymura Investors R&D Science Day
Dr Jordi Monés MD, PhD, the Director of the Institut de la Màcula, took part at the Iveric Bio Zymura Investors R&D Science Day in New York to explain the impact caused by the atrophic late form of age-related macular degeneration (AMD)
The event saw the presentation of the results of the clinical trial with Zimura for geographic atrophy secondary to age-related macular degeneration (AMD).
“Geographic atrophy or atrophic AMD is a devastating disease that causes severe visual loss and blindness within a few years of diagnosis in the elderly population. Today, there is no treatment and it represents an urgent challenge for the ophthalmological research community, since it has become a real epidemic as a result of the increase in life expectancy,” Dr Monés said.
He added that “the late form of AMD currently affects 10 million people solely in Europe, while the disease in all its types affects 200 million worldwide, a figure that will rise to 300 million by 2050”.
Dr Monés expressed hope about the latest results of the IVERIC Bio Zimura Phase II clinical trial: “The recent positive results of the Phase II trial of Zimura with anti-C5 therapy for geographic atrophy provide hope of having an effective, safe therapy in the short term and thus being able to delay the progression of the disease and gain years of vision in affected patients.”
Dr Jordi Monés MD, PhD’s presentation included a video showing in an 80-year-old patient, who did not have the disease, the devastating progression towards atrophic AMD that leads to legal blindness in just five years:
The event was completed by a panel of retinologists who are experts in atrophic AMD. Dr Jordi Monés MD, PhD was joined by Dr Marco Zarbin MD, PhD, of the Institute of Ophthalmology & Visual Science of the New Jersey Medical School, Pravin Dugel MD, of Retinal Consultants of Arizona, Karl Csaky MD, PhD, of the Retina Foundation of the Southwest, Trent Woodruff, investigator at the University of Queensland, Glenn Jaffe MD, of the Duke Department of Ophthalmology, and Marc Buyse of the International Drug Development Institute.